SF3769 (Legislative Session 94 (2025-2026))

340B prescription drugs delivery restrictions prohibition

Related bill: HF3609

AI Generated Summary

Purpose

  • The bill aims to ensure drug manufacturers cannot restrict the delivery of 340B prescription drugs, adds enforcement mechanisms, and removes an expiration date on the related provision, making the access protections permanent.

Main Provisions

  • Adds a new Subdivision 4 (Subd.4) to Minnesota Statutes 2024 section 62J.96, defining “Violation as deceptive practice.” A violation of these provisions is treated as an unfair or deceptive trade practice under Minnesota Statutes 8.31(1) and can be enforced by the state attorney general.
  • Repeals Minnesota Statutes 2024 section 62J.96 subdivision 3 (the prior expiration provision).
  • Amends 62J.96 to address access to 340B drugs and to remove the expiration date by repealing the Subdivision that set an expiration.
  • The appendix notes that the prior Subd.3 Expiration (which stated the section would expire on July 1, 2027) is repealed, resulting in permanent protections.

Significant Changes to Existing Law

  • Removes the expiration mechanism that previously limited the 340B access provisions, making the protections permanent.
  • Elevates noncompliance by drug manufacturers (restricting delivery of 340B drugs) to the level of deceptive trade practices, subject to enforcement by the attorney general.
  • Repeals a specific subdivision (Subd.3) of 62J.96 to accomplish these changes.

Practical Impact

  • Drug manufacturers would be prohibited from restricting how 340B prescription drugs are delivered.
  • Violations could be pursued as unfair or deceptive trade practices, with enforcement by the Minnesota Attorney General.
  • The policy change removes any time limit, ensuring the 340B access protections are permanent.

Enforcement and Oversight

  • Enforcement authority rests with the Minnesota Attorney General under the state's consumer protection framework for deceptive trade practices.

Relevant Terms 340B drugs drug manufacturers delivery of drugs access to 340B unfair or deceptive trade practice deceptive trade practice Minnesota Statutes 62J.96 Subd.4 Subd.3 Expiration repealer attorney general enforcement 340B program

Bill text versions

Past committee meetings

Actions

DateChamberWhereTypeNameCommittee Name
February 23, 2026SenateActionIntroduction and first reading
February 23, 2026SenateActionReferred toCommerce and Consumer Protection
February 26, 2026SenateActionAuthor added
March 05, 2026SenateActionComm report: To pass and re-referred toJudiciary and Public Safety
March 23, 2026SenateActionComm report: To pass
March 23, 2026SenateActionSecond reading

Citations

 
[
  {
    "analysis": {
      "added": [
        "New Subd. 4: Violation as deceptive practice.",
        "Defines enforcement by the attorney general under Minn. Stat. §8.31, subd. 1."
      ],
      "removed": [],
      "summary": "Adds a new subdivision to Minn. Stat. §62J.96 defining 'Violation as deceptive practice' and makes such violations subject to enforcement as unfair or deceptive trade practices.",
      "modified": [
        "Amends §62J.96 by adding Subd. 4."
      ]
    },
    "citation": "62J.96",
    "subdivision": "subd. 4"
  },
  {
    "analysis": {
      "added": [],
      "removed": [
        "Subd. 3 is repealed."
      ],
      "summary": "Repeals Minn. Stat. §62J.96, subd. 3.",
      "modified": [
        "§62J.96, subd. 3 repealed."
      ]
    },
    "citation": "62J.96",
    "subdivision": "subd. 3"
  },
  {
    "analysis": {
      "added": [],
      "removed": [],
      "summary": "References Minn. Stat. §8.31, subd. 1 for enforcement of unfair or deceptive trade practices, used here to authorize enforcement of new deceptive-practice violation in §62J.96, subd. 4.",
      "modified": [
        "Uses §8.31, subd. 1 as the basis for enforcement of deceptive-practice violations under §62J.96, subd. 4."
      ]
    },
    "citation": "8.31",
    "subdivision": "subd. 1"
  }
]

Progress through the legislative process

17%
In Committee
Loading…